MDMA-assisted psychotherapy has rapidly emerged as one of the most promising approaches for addressing trauma and related mental health conditions. While public interest has grown due to media coverage and personal testimonials, a strong body of scientific research now provides deeper insight into its safety, efficacy, and long-term impact. For those curious about the evidence behind this evolving field, this curated list of 15 peer-reviewed studies offers a comprehensive entry point.
Spanning clinical trials, long-term follow-ups, qualitative reports, and meta-analyses, these papers explore MDMA’s use primarily in the treatment of PTSD, though many also shed light on its broader therapeutic potential. They highlight not only symptom reduction but also lasting psychological transformation, improved relational capacities, and shifts in worldview. While some studies use structured approaches like cognitive behavioural therapy (CBT), others take a more integrative or experiential view.
Together, these studies provide a solid scientific foundation for understanding the therapeutic value of MDMA when administered in a controlled, supportive setting. Whether you are a prospective retreat participant, therapist, researcher, or simply curious, this selection of evidence is designed to inform and deepen your understanding of this powerful modality.
Review of Meta-Reviews (2025)
Yong, A. S. J., Bratuskins, S., Sultani, M. S., et al. (2025). Safety and efficacy of MDMA‑assisted psychotherapy for PTSD: overview of systematic reviews and meta‑analyses. Australian & New Zealand Journal of Psychiatry.
Synthesising 14 meta‑analyses encompassing over 350 participants, this umbrella review confirmed consistent large effects in symptom reduction, response, and remission. Adverse effects were minimal and mostly short-lived. However, the authors note most trials were authored/supported by the same organisation, calling for independent replication and broader funding to validate these findings.
Safety & Efficacy Umbrella Review (2024)
Bahji, A., Forsyth, A., Groll, D., & Hawken, E. R. (2020 [2024]). Efficacy of MDMA‑assisted psychotherapy for PTSD: Systematic review & meta‑analysis. Progress in Neuro‑Psychopharmacology & Biological Psychiatry, 96, 109735.
A comprehensive meta‑analysis summarising RCTs through October 2023 confirmed that MDMA-assisted psychotherapy significantly outperforms controls in reducing PTSD symptoms. Side effects were generally mild and short-lived. While confirming clinical promise, the review underscores the importance of more diverse, independently funded trials.
Functional Neuroimaging Study (2023)
Singleton, S. P., Wang, J. B., Mithoefer, M. C., et al. (2023). Altered brain activity and functional connectivity after MDMA‑assisted therapy for PTSD. Frontiers in Psychiatry, 13, 947622.
In veterans with chronic PTSD, fMRI scans before and two months after MDMA-assisted therapy showed increased amygdala-posterior cingulate and amygdala-insula connectivity – brain changes correlated with symptom improvement. Reduced trauma-based activation in the visual cortex also emerged. These findings support mechanistic links between brain re-modelling and clinical recovery.
Meta‑Analysis Review (2021)
Illingworth, B. J. G., Lewis, D. J., Lambarth, A. T., et al. (2021). MDMA‑assisted psychotherapy vs psychotherapy alone in treatment‑resistant PTSD: systematic review and meta‑analysis. Journal of Psychopharmacology, 35(5), 501–511.
Reviewing five RCTs (n≈106), this meta‑analysis found large standardised effect sizes (≈1.3), significantly higher response and remission rates compared to therapy alone. Short-term side effects (jaw tightness, nausea) were mild and resolved quickly; severe events were rare. The analysis offers strong quantitative support for MDMA-assisted therapy’s effectiveness in treatment-resistant populations.
Phase 3 RCT: Severe PTSD (2021)
Mitchell, J. M., Boenschutz, M., Lilienstein, A., et al. (2021). MDMA‑assisted therapy for severe PTSD: a randomized, double‑blind, placebo‑controlled phase 3 study. Nature Medicine, 27, 1025–1033.
A pivotal Phase 3 trial with 90 participants comparing MDMA-assisted therapy to placebo plus therapy showed 67% of the MDMA group no longer met PTSD criteria versus 32% of placebo at 18 weeks. PTSD symptom severity decreased significantly more in the MDMA group. Side effects were mild and transient; treatment was well-tolerated. This is the strongest clinical evidence to date supporting MDMA’s therapeutic use under controlled conditions.
Clinical Commentary on Phase 3 Results (2021)
Krystal, J. H., Kelmendi, B., Petrakis, I. L. (2021). Psychotherapy‑supported MDMA treatment for PTSD. Cell Reports Medicine, 2(8), 100378.
This expert commentary contextualises the Phase 3 findings, emphasising the dramatic symptom reduction (55% vs. 31%) among MDMA recipients. The authors note MDMA’s safety when delivered with therapy, highlight unresolved questions about optimal dosing and mechanisms, and urge continued neurobiological study to refine treatment models.
MDMA Life‑Threatening Illness Distress Pilot (2020)
Wolfson, P. E., Andries, J., Feduccia, A. A., et al. (2020). MDMA‑assisted psychotherapy for treatment of anxiety and other psychological distress related to life‑threatening illnesses: a randomized pilot study. Scientific Reports, 10, 1–13.
Terminally ill patients who received MDMA-assisted therapy experienced significant reductions in anxiety and depression. Participants reported greater emotional resilience, acceptance, and improved quality of life compared to controls. Adverse effects were mild and transient. This preliminary RCT indicates MDMA may help with existential distress in contexts beyond PTSD.
Couples Therapy Case Study (2019)
Wagner, A. C., Mithoefer, M. C., Monson, C. M. (2019). Combining Cognitive‑Behavioral Conjoint Therapy for PTSD with MDMA‑assisted psychotherapy: Care case example. Journal of Psychoactive Drugs, 51(2), 190–197.
A case example of six couples (one partner with PTSD) using MDMA-assisted couples therapy combined with cognitive-behavioural conjoint therapy showed marked symptom improvement, increased intimacy, and communication. Non-PTSD partners noted reduced conflict and greater emotional support, suggesting potential for couple-based MDMA protocols.
Life Improvements Beyond Symptom Relief (2019)
Barone, W., Mitsunaga-Whitten, M., Blaustein, L. O., Perl, P., Swank, M., & Swift, T. C. (2019). Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: qualitative follow-up of a clinical trial for individuals with treatment-resistant PTSD. Journal of Psychoactive Drugs, 51(2), 180–191.
In this follow-up study, participants who had completed MDMA-assisted therapy for treatment-resistant PTSD reported enduring benefits a year after treatment. Beyond reduced PTSD symptoms, they described lasting positive changes in relationships, self-perception, emotional openness, and overall well-being. Many felt more capable of engaging with life, processing emotions, and relating authentically to others. Importantly, no participants reported long-term adverse effects or dependence. This study underscores that MDMA therapy’s value may extend beyond clinical metrics, offering deep psychological healing relevant for retreat contexts focusing on whole-person growth.
Phase 2 RCT in First Responders (2018)
Mithoefer, M. C., Mithoefer, A. T., Feduccia, A. A., et al. (2018). MDMA‑assisted psychotherapy for PTSD in veterans, firefighters, and police officers: a randomized, double‑blind, dose‑response, phase 2 clinical trial. Lancet Psychiatry, 5(6), 486–497.
A landmark Phase 2 trial in first responders with chronic PTSD showed that MDMA-assisted therapy significantly increased treatment response and remission rates compared to placebo. Most participants no longer met PTSD criteria after treatment, with low risks and sustained symptom relief, strengthening the case for larger Phase 3 trials.
Pilot Study: Autism & Social Anxiety (2018)
Danforth, A. L., Struble, C., Yazar‑Klosinski, B., et al. (2018). Reduction in social anxiety after MDMA‑assisted psychotherapy with autistic adults: a randomized, double‑blind, placebo‑controlled pilot study. Psychopharmacology, 235(11), 3137–3148.
In autistic adults with severe social anxiety, two 8‑hour MDMA-assisted sessions led to large and durable social anxiety reductions versus placebo. Effect sizes were very large (d ≈ 1.4). Participants reported improved confidence and connection. No serious adverse events observed. This pilot opens potential application of MDMA therapy beyond PTSD into social functioning domains.
Mechanisms Review: Memory & Fear Extinction (2018)
Feduccia, A. A., Holland, J., Mithoefer, M. C. (2018). Mechanisms of memory reconsolidation and fear extinction in MDMA‑assisted psychotherapy for PTSD. Progress in Neuro‑Psychopharmacology & Biological Psychiatry, 84, 221–228.
This review connects MDMA’s pharmacological effects (e.g., oxytocin and BDNF release) with enhanced fear extinction and memory re-consolidation processes. By dampening activity in fear-related brain regions and strengthening connectivity, MDMA appears to create safe conditions for emotional processing of trauma, offering a biologically plausible explanation for its therapeutic efficacy.
Safety Pharmacology Review (2018)
Vizeli, P., & Liechti, M. E. (2018). Safety pharmacology of acute MDMA administration in humans: meta‑analysis and systematic overview. Journal of Psychopharmacology, 32(9), 974–988.
Analysing controlled dosing studies, this review found that acute MDMA administration at clinical doses is generally safe. Common short-term effects included increased heart rate, jaw clenching, and nausea – transient and non-serious. No enduring cardiac or neuro-cognitive harm was detected. The findings support safety under clinical conditions
Durability Follow-Up (2013)
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., et al. (2013). Durability of improvement in PTSD symptoms and absence of harmful effects or drug dependency after MDMA‑assisted psychotherapy: a prospective long‑term follow‑up study. Journal of Psychopharmacology, 27(1), 28–39.
This follow-up tracked participants for 17 to 74 months after MDMA therapy. Most maintained dramatic PTSD relief; average CAPS‑IV scores remained low with no relapse in most cases. Quality of life, mood, and personality improvements persisted. Crucially, no dependence or serious adverse effects were observed, highlighting long-term benefit from limited sessions.
Pilot RCT in Chronic PTSD (2011)
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., et al. (2011). The safety and efficacy of ±3,4‑methylenedioxymethamphetamine‑assisted psychotherapy in subjects with chronic, treatment‑resistant PTSD: a randomized controlled pilot study. Journal of Psychopharmacology, 25(4), 439–452.
The first modern controlled trial tested MDMA-assisted therapy in treatment-resistant PTSD patients. Participants receiving MDMA plus therapy exhibited significant reductions in PTSD symptoms versus low-dose controls. Effects were rapid and persisted through follow-up. Importantly, the treatment was well tolerated without severe adverse events. These results established safety parameters and paved the way for larger trials.
Psilocybin Retreat in the Netherlands
TAKE THE FIRST STEP
Get the monthly email with tools to help you live a more conscious life.
Just useful stuff – we promise!
Contact Us
Email: contact@consciousgrowth.eu
Legal Note
Taking psychedelic truffles in our retreats is subject to a registration process. Please consult the FAQs for a list of contraindications. Conscious Growth does not offer therapy or treatment for physical or mental health conditions during the retreats.
In accordance with Dutch law, we use exclusively psilocybin truffles that are legal across the country. You can read more about the legal aspect here.
APPLY for a Retreat
Book an Introductory Call
Our Retreats
Frequently Asked Questions
Resources
Terms and Conditions
Privacy Policy